|
Healthy People 2030, Substance Use Working Group
|
Committee, Work group, Advisory group, or Task Force
|
IOS/ODPHP, CDC, SAMHSA
|
NIDA
|
Members of the Substance Use (SU) Workgroup have expertise in areas including biostatistics, epidemiology, addiction neuroscience, substance use prevention and treatment, alcohol and drug policy, and health disparities. They developed the objectives related to substance use and substance use disorders, and they’ll provide data to track progress toward achieving these objectives throughout the decade.
|
|
Healthy People Initiative – Vision Health
|
Health Survey
|
CDC, AHRQ
|
NEI
|
Healthy People Initiative is a collaboration with the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ) to survey and measure public health outcomes for a variety of common diseases over the current decade. The National Eye Institute's (NEI) goal for this program is to Improve the visual health of the Nation through prevention, early detection, timely treatment, and rehabilitation.
|
|
Healthy Vision Month
|
Public Education Campaign
|
CDC
|
NEI
|
Each May the National Eye Institute (NEI) sponsors Healthy Vision Month (HVM), which is a national observance designed to elevate eye health as a priority for Americans. The National Institutes of Health (NIH) has worked with the Centers for Disease Control and Prevention (CDC) and recently with the Office of the Surgeon General to spotlight on the connection between eye health and overall health.
|
|
Helicobacter pylori Genome Project
|
Research Initiative
|
CDC
|
NCI, NLM
|
Investigators in the Infections and Immunoepidemiology Branch and the Metabolic Epidemiology Branch of DCEG are undertaking a joint effort to catalog comprehensively bacterial genetic and epigenetic variation potentially related to long-term outcomes of infection. Isolates from patients with gastric cancer or advanced premalignant lesions are compared to controls with benign infection (superficial gastritis) from the same geographic area. The study goal is to sequence 1000 strains representing both high and low gastric cancer risk populations worldwide, with over 300 isolates from 16 different countries completed to date. An international team of experts is collaborating on analyses of these complex data to identify associations with the gastric carcinogenesis cascade.
|
|
Hematopoietic Stem Cell Transplantation (HSCT) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, CDC, FDA
|
CC, NCI, NHLBI, NIAID
|
Interagency workgroup to discuss hematopoietic cell therapy advances and challenges across the federal workspace. Chair: Shelley Grant, Supervisory Public Health Analyst, HRSA’s Division of Transplantation. Background: The HSCT Workgroup is comprised of various government agencies and was created to share and collaborate on matters pertaining to hematopoietic blood stem cell transplantation and donation. The HSCT WG is chaired by HRSA and meets twice per year. The workgroup includes representatives: from Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Food and Drug Administration, National Institutes of Health, Office of Assistant Secretary for Health, Office of Assistance Secretary for Preparedness and Response, the U.S. Department of Defense – Navy, and the Department of Veterans Affairs.
|
|
Hepatitis B Research Network
|
Research Initiative
|
CDC
|
NCI, NIDDK
|
The Hepatitis B Research Network (HBRN), supported by NIDDK, was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brought together clinical centers from throughout the US and Canada. This multi-center Network enrolled patients in multiple clinical trials in both adults and children with hepatitis B. The Network is currently completing and publishing analyses from these trials.
|
|
HHS Action Plan for Cessation Committee
|
Committee, Work group, Advisory group, or Task Force
|
OASH
|
NCI
|
Group convened to lead the development of an action plan to support and accelerate smoking cessation.
|
|
HHS Agency Priority Goals Maternal Health
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, OASH, OGA
|
NICHD, OD/DPCPSI/OEPR, OD/IMOD
|
HHS-wide group to set an impact statement and priority goals regarding maternal morbidity and mortality.
|
|
HHS Artificial Intelligence Task Force
|
Committee, Work group, Advisory group, or Task Force
|
OS, ACF, ASPR, CDC, FDA, ONC
|
NCATS, NCI, NIAID, NIAMS, NIBIB, NLM, OD/DPCPSI/ODSS, OD/OSP
|
The HHS AI Task Force provides directional guidance (e.g., steering, strategy) and operational accountability to HHS on responsible use of AI in the HHS sector, in line with direction from HHS senior leaders; inform HHS senior leader decision-making on major resource allocations or other significant decisions. It is composed of a Program Management Office, Steering Committee, and the following Working Groups: Biosafety & Biosecurity, Critical Infrastructure & Cybersecurity, Drug & Device, HHS Service & Delivery, Internal Operations, Public Health, and Research & Discovery. Language requiring HHS to stand up the task force came from EO 14110 (AI EO): The Secretary of HHS shall, in consultation with the Secretary of Defense and the Secretary of Veterans Affairs, establish an HHS AI Task Force that shall, within 365 days of its creation, develop a strategic plan that includes policies and frameworks—possibly including regulatory action, as appropriate—on responsible deployment and use of AI and AI-enabled technologies in the health and human services sector (including research and discovery, drug and device safety, healthcare delivery and financing, and public health).
|
|
HHS Artificial Intelligence Task Force (AI TF): Research and Discovery Working Group (R&D WG)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, FDA, HRSA, OGC, SAMHSA
|
NIAID
|
Launched in January 2024, the Task Force aims to:1. Develop policies for harnessing AI potential while managing risks.2. Advance quality and safety standards for AI in health.3. Utilize policy tools and funding to promote ethical AI development and use.4. Educate the public on AI in health and human services.5. Deploy AI to enhance HHS mission fulfillment, ensuring quality and equity.These objectives are designed to integrate HHS efforts into a broader strategy for improving health services through ethical, safe, and effective use of AI.
|